Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Circulerend tumor-DNA toont maanden eerder dan scan of kankertherapie effectief is
nov 2023 | Dermato-oncologie, Uro-oncologie